Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
$1.56
$4.00
$0.92
▼
$16.95
$29.71M0.481.52 million shs152,321 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$0.96
-10.3%		$1.17
$0.84
▼
$2.46
$16.01M1.53179,369 shs114,353 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
0.00%0.00%0.00%0.00%-85.17%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%-7.68%-19.32%-21.30%-3.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
$1.56
$4.00
$0.92
▼
$16.95
$29.71M0.481.52 million shs152,321 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$0.96
-10.3%		$1.17
$0.84
▼
$2.46
$16.01M1.53179,369 shs114,353 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
0.00%0.00%0.00%0.00%-85.17%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%-7.68%-19.32%-21.30%-3.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
0.00
N/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.75
Moderate Buy$10.00941.56% Upside

Current Analyst Ratings Breakdown

Latest MRKR, ARAV, and MLND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/19/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/15/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
10/2/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/18/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
9/4/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/6/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M4.51N/AN/A$1.01 per share0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
-$36.41MN/AN/AN/AN/AN/A-91.03%-72.44%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.41N/AN/AN/AN/A-56.96%-47.82%11/12/2026 (Estimated)

Latest MRKR, ARAV, and MLND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.12N/AN/AN/A$2.12 millionN/A
8/14/2026Q2 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.25-$0.09+$0.16-$0.09$0.68 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
6.39
6.39
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.03
6.03

Institutional Ownership

CompanyInstitutional Ownership
Aravive, Inc stock logo
ARAV
Aravive
35.80%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%

Insider Ownership

CompanyInsider Ownership
Aravive, Inc stock logo
ARAV
Aravive
60.40%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
1219.04 millionN/ANot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable

Recent News About These Companies

Marker Therapeutics Secures $2.6 Mln FDA Grant To Support Phase 1 Of Pancreatic Cancer Study
October 19, 2026  |  rttnews.comhttps://www.rttnews.com/3700117/marker-therapeutics-secures-2-6-mln-fda-grant-to-support-phase-1-of-pancreatic-cancer-study.aspx
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
October 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/marker-therapeutics-awarded-2-6-110000783.html
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
October 16, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3010009/all-you-need-to-know-about-marker-therapeutics-mrkr-rating-upgrade-to-strong-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_12_zacks_rank_upgrade-3010009
New Strong Buy Stocks for October 16th
October 16, 2026  |  zacks.comhttps://www.zacks.com/commentary/3007913/new-strong-buy-stocks-for-october-16th?cid=cs-stocknewsapi-ft-zacks_1_rank_additions-3007913
Marker Highlights Expanded Manufacturing Support For MT-601
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692987/marker-highlights-expanded-manufacturing-support-for-mt-601.aspx
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366273/0/en/marker-therapeutics-highlights-expanded-manufacturing-support-of-cdmo-partner-following-formation-of-kincellis-advanced-therapies.html
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)
August 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRKR/pressreleases/3969567/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-and-cspc-pharmaceutical-group-otherchjtf/
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
June 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2943342/zacks-industry-outlook-indivior-aurinia-ironwood-altimmune-and-marker?cid=cs-stocknewsapi-ft-press_releases-2943342
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
June 25, 2026  |  zacks.comhttps://www.zacks.com/commentary/2942605/5-small-drug-stocks-to-invest-in-amid-a-biotech-comeback?cid=cs-stocknewsapi-ft-industry_outlook-2942605
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2924277/marker-therapeutics-mrkr-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2924277
Marker Therapeutics Sets Date for 2026 Annual Meeting
May 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRKR-Q/pressreleases/141978/marker-therapeutics-sets-date-for-2026-annual-meeting/
Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/marker-therapeutics-mrkr-price-target-decreased-by-12-83-to-8-02/ar-AA20ulsd
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
March 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2886298/marker-therapeutics-inc-mrkr-reports-q4-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2886298
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology
March 18, 2026  |  quiverquant.comQ
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258655/0/en/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results.html
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/18/3240173/0/en/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference.html
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/good-morning-america-features-baylor-college-of-medicine-pancreatic-cancer-study-utilizing-marker-therapeutics-mar-t-cell-technology-1035745259
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)
January 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/37179524/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-pasithea-therapeutics-corp-ktta-and-transmedics-group-tmdx/
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
January 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2820215/mrkr-stock-up-nearly-114-in-3-months-here-s-what-you-need-to-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2820215
Marker Therapeutics, Inc. Common Stock (MRKR)
January 9, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/mrkr/insider-activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 10/23/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Millendo Therapeutics stock logo

Millendo Therapeutics NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$0.96 -0.11 (-10.27%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$0.97 +0.01 (+1.03%)
As of 10/23/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas